« Return to News | Drug Sponsors

MiReven, Silence to evaluate delivery of novel microRNA-based therapeutics

Wednesday, August 22, 2012 02:05 PM

Silence Therapeutics, an RNA interference (RNAi) therapeutics company, has signed an agreement with MiReven, an Australian-based microRNA company, to assess the delivery potential of Silence's proprietary delivery systems with MiReven's novel microRNA-based therapeutics.

MiReven commerciales discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7. Through the agreement, Silence will formulate a miR-7 mimetic (a potentially therapeutic mimic of the miR-7 molecule) with its proprietary AtuPLEX, DACC and DBTC delivery systems in order to evaluate miR-7 in various cancer models. Silence will undertake in vitro and in vivo studies of the formulated miR-7.

"This is the fourth collaboration that we have recently signed to explore the use of Silence's delivery technologies for microRNAs,” said Klaus Giese, CSO of Silence Therapeutics. “Functional delivery to target cells is widely recognized as one of the greatest challenges facing most nucleic acid therapies. Our three proprietary RNAi delivery systems, AtuPLEX, DACC and DBTC, deliver effective doses of RNAi to key intracellular targets in vascular endothelium, lung and liver respectively, and provide our partners with a growing range of solutions to overcome their delivery challenges."

Silence is being paid an undisclosed fee for the collaboration.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.